Our data showed that high levels of DYRK1A might be related to poor overall survival in patients with lung cancer, and the DYRK1A inhibitor harmine could suppress the proliferation of NSCLC cells. The gene discussed is DYRK1A; the disease is non-small cell lung carcinoma.